BeiGene dives in on natural killer cells with discovery pact for small biotech's stem cell-based platform

China’s BeiGene has been busy on the oncology front in recent years, looking to keep up with the pack with one late-stage PD-1 on the way to a filing and a slate of small deals fleshing out the pipeline. Now, with its eyes on the horizon, the drugmaker has snared an early-stage pact for a clutch of next-gen cell therapies.